

# Public Meeting on Patient-Focused Drug Development for Psoriasis



March 17, 2016

10:00 = 10:05 am   Welcome   Sara Eggers, PhD   Office of Strategie Programs (OSP), Center for Drug Evaluation and Research (CDER), FDA	9:00 – 10:00 am	Registration
Sara Fegers, PhD Office of Strategic Programs (OSP), Center for Drng Evaluation and Research (CDER), FDA  10:05 = 10:10 am Opening Remarks Kendall Marcus, MD Director, Division of Dermatology and Dental Products (DDDP), CDER, FDA  10:10 = 10:20 am Overview of FDA's Patient-Focused Drug Development Initiative Theresa Mullin, PhD Director, OSP, CDER, FDA  10:20 = 10:35 am An Overview of Psoriasis and Available Treatments Jane Liedtka, MD DDDP, CDER, FDA  10:35 = 10:40 am The Road from PFDD Meetings to Clinical Trial Endpoints Yasmin Choudhry, MD Clinical Outcome: Assassment (COA) Staff. Office of New Drugs (OND), CDER, FDA  10:40 = 10:45 am Overview of Discussion Format Sara Fegers, PhD OSP, CDER, FDA  10:45 = 11:15 am Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 = 12:30 pm Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 = 1:30 pm Lunch  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 = 2:05 pm Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 = 3:20 pm Open Public Comment  Closing Remarks Kendall Marcus, MID	7.00 – 10.00 am	Registration
Office of Strategic Programs (OSP), Center for Drug Evaluation and Research (CDER), FDA  10:05 – 10:10 am  Opening Remarks Kendall Marcus, MD Director, Divisions of Dermatology and Dental Products (DDDP), CDER, FDA  10:10 – 10:20 am  Overview of FDA's Patient-Focused Drug Development Initiative Theresa Mullin, PhD Director, OSP, CDER, FDA  10:20 – 10:35 am An Overview of Psoriasis and Available Treatments Jane Liedtla, MD DDDP, CDER, FDA  10:35 – 10:40 am The Road from PFDD Meetings to Clinical Trial Endpoints Yasmin Choudhry, MD Clinical Outcomes Assessment (COA) Staff. Office of New Drugs (OND), CDER, FDA  10:40 – 10:45 am Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am Panel #1 Discussion on Topic 1 Topic 1: Discase symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  Lunch  1:30 – 1:35 pm Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm Large-Group Facilitated Discussion: Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm Open Public Comment  Closing Remarks Kendall Marcus, MD	10:00 – 10:05 am	
10:05 – 10:10 am  Opening Remarks Kendall Marcus, MD Diriston, Division of Dermatology and Dental Products (DDDP), CDER, FDA  10:10 – 10:20 am  Overview of FDA's Patient-Focused Drug Development Initiative Theresa Mullin, PhD Diriston, OSP, CDER, FDA  10:20 – 10:35 am  An Overview of Psoriasis and Available Treatments Jane Liceltka, MD DDDP, CDER, FDA  10:35 – 10:40 am  The Road from PFDD Meetings to Clinical Trial Endpoints Yasmin Choudhry, MD Clinical Outcomes Assessment (COA) Staff. Office of New Drugs (OND), CDER, FDA  10:40 – 10:45 am  Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am  Panel #1 Discussion on Topic 1 Topic 1: Discase symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  Lunch  1:30 – 1:30 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD		
Kendall Marcus, MID   Director, Division of Dermatology and Dental Products (DDDP), CDER, FDA		Office of Strategic Programs (OSP), Center for Drug Evaluation and Research (CDER), FDA
New John Color   New John Color	10:05 – 10:10 am	Opening Remarks
10:10 – 10:20 am		
Theresa Mullin, PhD Director, OSP, CDER, FDA  10:20 – 10:35 am  An Overview of Psoriasis and Available Treatments Jane Liedtka, MD DDDP, CDER, FDA  10:35 – 10:40 am  The Road from PFDD Meetings to Clinical Trial Endpoints Yasmin Choudhry, MD Clinical Outcomes Assessment (COA) Staff: Office of New Drage (OND), CDER, FDA  10:40 – 10:45 am  Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am  Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD		Director, Division of Dermatology and Dental Products (DDDP), CDER, FDA
Theresa Mullin, PhD Director, OSP, CDER, FDA  10:20 – 10:35 am  An Overview of Psoriasis and Available Treatments Jane Liedtka, MD DDDP, CDER, FDA  10:35 – 10:40 am  The Road from PFDD Meetings to Clinical Trial Endpoints Yasmin Choudhry, MD Clinical Outcomes Assessment (COA) Staff: Office of New Drage (OND), CDER, FDA  10:40 – 10:45 am  Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am  Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD	10:10 10:20 am	Overview of EDA's Patient Focused Drug Development Initiative
10:20 – 10:35 am  An Overview of Psoriasis and Available Treatments Jane Liedtka, MD DDDP, CDER, FDA  10:35 – 10:40 am  The Road from PFDD Meetings to Clinical Trial Endpoints Yasmin Choudhry, MD Clinical Outcomes Assessment (COA) Staff. Office of New Drugs (OND), CDER, FDA  10:40 – 10:45 am  Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am  Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:35 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD	10.10 – 10.20 am	
Jane Liedtka, MD DDDP, CDER, FDA  10:35 – 10:40 am The Road from PFDD Meetings to Clinical Trial Endpoints Yasmin Choudhry, MD Clinical Outcomes Assessment (COA) Staff. Office of New Drugs (OND), CDER, FDA  10:40 – 10:45 am Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  Lunch  1:35 – 1:35 pm Afternon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm Open Public Comment  Closing Remarks Kendall Marcus, MD		·
Jane Liedtka, MD DDDP, CDER, FDA  10:35 – 10:40 am The Road from PFDD Meetings to Clinical Trial Endpoints Yasmin Choudhry, MD Clinical Outcomes Assessment (COA) Staff. Office of New Drugs (OND), CDER, FDA  10:40 – 10:45 am Overview of Discussion Format Sara Eggers, PhD ONP, CDER, FDA  10:45 – 11:15 am Panel #1 Discussion on Topic 1 Topic 1: Discase symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm Afternon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm Open Public Comment  Closing Remarks Kendall Marcus, MD		
10:35 – 10:40 am  The Road from PFDD Meetings to Clinical Trial Endpoints Yasmin Choudhry, MD Clinical Outcomes Assessment (COA) Staff. Office of New Drugs (OND), CDER, FDA  10:40 – 10:45 am  Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am  Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  Lunch  1:30 – 1:35 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD	10:20 – 10:35 am	
10:35 – 10:40 am The Road from PFDD Meetings to Clinical Trial Endpoints Yasmin Choudhry, MD Clinical Outcomes Assessment (COA) Staff. Office of New Drugs (OND), CDER, FDA  10:40 – 10:45 am Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:35 pm Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm Open Public Comment  Closing Remarks Kendall Marcus, MD		
Yasmin Choudhry, MD Clinical Outcomes Assessment (COA) Staff. Office of New Drugs (OND), CDER, FDA  10:40 – 10:45 am Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm Lunch  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm Open Public Comment  Closing Remarks Kendall Marcus, MD		DDDI, CDER, I DA
Clinical Outcomes Assessment (COA) Staff. Office of New Drugs (OND), CDER, FDA  10:40 – 10:45 am  Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am  Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD	10:35 – 10:40 am	The Road from PFDD Meetings to Clinical Trial Endpoints
10:40 – 10:45 am  Overview of Discussion Format Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am  Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm  Lunch  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD		•
Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm Lunch  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm Open Public Comment  Closing Remarks Kendall Marcus, MD		Clinical Outcomes Assessment (COA) Staff. Office of New Drugs (OND), CDER, FDA
Sara Eggers, PhD OSP, CDER, FDA  10:45 – 11:15 am Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm Lunch  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm Open Public Comment  Closing Remarks Kendall Marcus, MD	10:40 – 10:45 am	Overview of Discussion Format
10:45 – 11:15 am  Panel #1 Discussion on Topic 1 Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  Lunch  1:30 – 1:35 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD		
Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm  Lunch  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD		OSP, CDER, FDA
Topic 1: Disease symptoms and daily impacts that matter most to patient. A panel of patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm  Lunch  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD	10.45 11.15	Daniel #1 Diagnosian on Tanie 1
patients will provide comments to start the discussion.  11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  3:50 – 4:00 pm  Closing Remarks Kendall Marcus, MD	10:45 – 11:15 am	<u>=</u>
11:15 – 12:30 pm  Large-Group Facilitated Discussion: Topic 1 Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm  Lunch  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  3:50 – 4:00 pm  Closing Remarks Kendall Marcus, MD		
Patients and patient representatives in the audience will be invited to add to the dialogue.  12:30 – 1:30 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  3:50 – 4:00 pm  Closing Remarks Kendall Marcus, MD		
dialogue.  12:30 – 1:30 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  3:50 – 4:00 pm  Closing Remarks Kendall Marcus, MD	11:15 – 12:30 pm	
1:30 – 1:30 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  3:50 – 4:00 pm  Closing Remarks Kendall Marcus, MD		* *
1:30 – 1:35 pm  Afternoon Welcome Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  3:50 – 4:00 pm  Closing Remarks Kendall Marcus, MD	12:30 – 1:30 pm	
Sara Eggers, PhD OSP, CDER, FDA  1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  3:50 – 4:00 pm  Closing Remarks Kendall Marcus, MD	12.50 1.50 pm	2 dileti
1:35 – 2:05 pm  Panel #2 Discussion on Topic 2 Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  3:50 – 4:00 pm  Closing Remarks Kendall Marcus, MD	1:30 – 1:35 pm	
1:35 – 2:05 pm  Panel #2 Discussion on Topic 2  Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2  Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  3:50 – 4:00 pm  Closing Remarks  Kendall Marcus, MD		
Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD		OSP, $CDER$ , $FDA$
Topic 2: Patient perspectives on current approaches to treating psoriasis. A panel of patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  Closing Remarks Kendall Marcus, MD	1:35 – 2:05 pm	Panel #2 Discussion on Topic 2
patients will provide comments to start the discussion  2:05 – 3:20 pm  Large-Group Facilitated Discussion: Topic 2 Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm  Open Public Comment  3:50 – 4:00 pm  Closing Remarks Kendall Marcus, MD	2.00 P.2.	
Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm		patients will provide comments to start the discussion
Patients and patient representatives in the audience will be invited to add to the dialogue.  3:20 – 3:50 pm	2:05 2:20 am	Lawre Crown Facilitated Discoverions Tonic 2
dialogue.  3:20 – 3:50 pm	2.03 – 3.20 pm	
3:50 – 4:00 pm Closing Remarks Kendall Marcus, MD		
3:50 – 4:00 pm Closing Remarks Kendall Marcus, MD	2.20	
Kendall Marcus, MD	3:20 – 3:50 pm	Open Public Comment
Kendall Marcus, MD	3:50 – 4:00 pm	Closing Remarks
	· · · · ·	
		DDDP, CDER, FDA

## **Discussion Questions**

## Topic 1: Disease symptoms and daily impacts that matter most to patients

- 1) Of all the symptoms that you experience because of your condition, which 1-3 symptoms have the most significant impact on your life? (Examples may include red, thickened, scaling skin, itching, burning or soreness, etc.)
- 2) Are there specific activities that are important to you but that you cannot do at all or as fully as you would like because of your condition? (Examples of activities may include sleeping through the night, daily hygiene, participation in sports or social activities, intimacy with a spouse or partner, etc.)
- 3) How do your symptoms and their negative impacts affect your daily life on the best days? On the worst days?
- 4) How have your condition and its symptoms changed over time?
  - a) Would you define your condition today as being well managed?
- 5) What worries you most about your condition?

#### Topic 2: Patients' perspectives on current approaches to treatment

- 1) What are you currently doing to help treat your condition or its symptoms? (Examples may include prescription medicines, over-the-counter products, phototherapy, and other therapies including non-drug therapies such as diet modification.)
  - a) How has your treatment regimen changed over time, and why?
- 2) How well does your current treatment regimen control your condition?
  - a) How well do your treatments address specific skin symptoms? Which symptoms are not addressed as well?
  - b) How well have these treatments worked for you as your condition has changed over time?
- 3) What are the most significant downsides to your current treatments, and how do they affect your daily life? (Examples of downsides may include going to the hospital or clinic for treatment, time devoted to treatment, etc.)
- 4) Assuming there is no complete cure for your condition, what specific things would you look for in an ideal treatment for your condition?
  - a) What would you consider to be a meaningful improvement (for example symptom improvements or functional improvements) in your condition that a treatment could provide?
- 5) What factors do you take into account when making decisions about selecting a course of treatment?
  - a) What information on the potential benefits of these treatments factors most into your decision?
  - b) How do you weigh the potential benefits of these treatments versus the common side effects of the treatments? (Common side effects could include headache, nausea, injection site reactions)
  - c) How do you weigh potential benefits of these treatments versus the less common but serious risks associated with the treatments? (Examples of less common but serious risks are infections, cancer, liver damage, kidney damage, birth defects, blood disorders, etc.)

#### **Docket Information**

We encourage you to submit your written comments to the docket by May 17, 2016: <a href="http://www.regulations.gov/#!documentDetail;D=FDA-2015-N-4166-0001">http://www.regulations.gov/#!documentDetail;D=FDA-2015-N-4166-0001</a> or go to <a href="http://www.regulations.gov">www.regulations.gov</a> and search for: **psoriasis patient-focused drug development.**